BIO-11006 is under clinical development by BioMarck Pharmaceuticals and currently in Phase II for Osteosarcoma. According to GlobalData, Phase II drugs for Osteosarcoma have a 13% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how BIO-11006’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Related Company Profiles

View all

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

BIO-11006 overview

BIO-11006 is under development for the treatment of  Osteosarcoma, Ewing Sarcoma. The drug candidate is administered as an aerosolized inhalational solution. The drug candidate is a crystalline, small soluble peptide with ten amino acids. It targets myristoylated alanine-rich C-kinase substrate (MARCKS) protein. It is derived from the N-terminal peptide of MARCKS protein.  The drug candidate is based on drug and disease target identification technology.
It was under development for the treatment of chronic obstructive pulmonary disease (COPD), acute respiratory distress syndrome, non-small cell lung cancer, pyoderma gangrenosum and coronavirus disease 2019 caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), uveitis, recurrent osteosarcoma, skin inflammation, atopic dermatitis, psoriasis, solid tumors.

BioMarck Pharmaceuticals overview

BioMarck Pharmaceuticals (BioMarck ) is a biopharmaceutical company that utilizes anti-MARCKS peptides for developing and licensing products targeted at difficult to treat diseases.

For a complete picture of BIO-11006’s drug-specific PTSR and LoA scores, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.